View in EDS

EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings.

Saved in:
Bibliographic Details
Title: EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings.
Authors: Crawford, S1 (AUTHOR), Li, H1 (AUTHOR), Srivastava, B1 (AUTHOR), Martin, P2 (AUTHOR), Gahn, J2 (AUTHOR), Rogers, KA3 (AUTHOR)
Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS74-S74. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 177910609
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Crawford%2C+S%22">Crawford, S</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+H%22">Li, H</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Srivastava%2C+B%22">Srivastava, B</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martin%2C+P%22">Martin, P</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gahn%2C+J%22">Gahn, J</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rogers%2C+KA%22">Rogers, KA</searchLink><relatesTo>3</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Value+in+Health%22">Value in Health</searchLink>. 2024 Supplement, Vol. 27 Issue 6, pS74-S74. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=177910609
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jval.2024.03.391
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S74
    Titles:
      – TitleFull: EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Crawford, S
      – PersonEntity:
          Name:
            NameFull: Li, H
      – PersonEntity:
          Name:
            NameFull: Srivastava, B
      – PersonEntity:
          Name:
            NameFull: Martin, P
      – PersonEntity:
          Name:
            NameFull: Gahn, J
      – PersonEntity:
          Name:
            NameFull: Rogers, KA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 06
              Text: 2024 Supplement
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 10983015
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Value in Health
              Type: main
ResultId 1